Acute Coronary Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Acute Coronary Syndrome is one of the most common diseases in developing countries. It is commonly known as a heart attack, and it occurs when there is a sudden blockage in blood flow in one or more of the coronary arteries, cutting off blood supply to a part of the heart muscle and causing necrosis. If the blockage is severe, the heart may stop beating. This is most commonly caused by occlusion or blockage of a coronary artery caused by a vulnerable atherosclerotic plaque rupture, an unstable collection of lipids and white blood cells in the artery wall. Myocardial infarction usually begins in the endocardium and spreads towards the epicardium. Acute myocardial infarction symptoms include chest pain that may spread to the shoulder, arm, back, neck, or jaw. This type of pain always begins in the center or left side of the chest and lasts a few minutes. The onset of symptoms in acute myocardial infarction is usually gradual, over several minutes, and rarely instantaneous.
The incidence of Acute Coronary Syndrome ranges
from 189 to 225 cases per 100,000 population in the USA.
The competitive
landscape of Acute Coronary Syndrome includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Acute
Coronary Syndrome across 8 MM market from the center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Acute
Coronary Syndrome Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No    Asset               Company                                 Stage
1          dalcetrapib        DalCor
Pharmaceuticals Phase 3
2          E5555   Eisai Inc.          Phase 2
3          Inclisiran           Novartis
Pharmaceuticals          Phase 3
4          Apolipoprotein A-I          CSL
Behring     Phase 3
5          Losmapimod     GlaxoSmithKline            Phase 3
6          TAK-442           Takeda Phase 2
7          MDCO-216       The
Medicines Company           Phase 2
8          Alirocumab        Regeneron
Pharmaceuticals      Phase 3
9          LC23-1306        LG
Life Sciences           Phase 1
10        SP-8008           Shin
Poong Pharmaceutical Co. Ltd.      Phase 1

Comments
Post a Comment